Skip to main navigation

MoonLake

e: info@moonlaketx.com

About us
Science
Investor relations

Site - Main

About us
Science
Investor relations

e: info@moonlaketx.com

INVESTOR RELATIONS

Press Releases

Year

All News
2026
2025
2024
2023
2022
2021

Nov 5 2025

MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering

Read More +

Nov 5 2025

MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab

Read More +

Sep 28 2025

MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody® sonelokimab

Read More +

Aug 5 2025

MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update

Read More +

May 12 2025

MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update

Read More +

Apr 25 2025

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29

Read More +

Apr 3 2025

MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates

Read More +

Feb 26 2025

MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

Read More +

Jan 8 2025

MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab

Read More +

Site - Investor Tools

Contact Us

MoonLake Immunotherapeutics Dorfstrasse 29, 6300 Zug, Schweiz/Switzerland

e: info@moonlaketx.com
media: media@moonlaketx.com
IR: ir@moonlaketx.com

Quick Links

Home
About us
Team
Science
Pipeline

Therapeutic focus
Investor relations
Careers
Privacy policy

© 2026 - MoonLake Immunotherapeutics

Privacy Policy